Abstract
Ebola virus is responsible for causing severe hemorrhagic fevers, with case fatality rates of up to 90%. Currently, no antiviral or vaccine is licensed against Ebola virus. A phosphatidylserine-targeting antibody (PGN401, bavituximab) has previously been shown to have broad-spectrum antiviral activity. Here, we demonstrate that PGN401 specifically binds to Ebola virus and recognizes infected cells. Our study provides the first evidence of phosphatidylserine-targeting antibody reactivity against Ebola virus.
Publication types
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Animals
-
Antibodies, Viral / immunology*
-
Antibodies, Viral / metabolism
-
Cell Line
-
Cells, Cultured
-
Chlorocebus aethiops
-
Ebolavirus / immunology*
-
Ebolavirus / metabolism
-
Flow Cytometry
-
Fluorescent Antibody Technique
-
Hemorrhagic Fever, Ebola / immunology
-
Hemorrhagic Fever, Ebola / virology
-
Humans
-
Phosphatidylserines / immunology*
-
Phosphatidylserines / metabolism
-
Protein Binding / immunology
-
Vero Cells
-
Virion / immunology*
-
Virion / metabolism
Substances
-
Antibodies, Viral
-
Phosphatidylserines